Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Maverick Capital Ltd.

Key Points

• Maverick Capital Ltd. significantly increased its stake in Teva Pharmaceutical Industries by 114.0% in Q1, acquiring an additional 16,137 shares and bringing its total holdings to 30,292 shares valued at $466,000.
• Institutional investors have shown heightened interest in Teva, with Harel Insurance Investments boosting its stake by a staggering 197,885.2%, now holding over 22 million shares worth approximately $339 million.
• Analysts remain optimistic about Teva, with several brokerages issuing "buy" ratings and raising target prices, resulting in a consensus rating of "Buy" with a target price of $24.71.

Maverick Capital Ltd. grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 114.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,292 shares of the company's stock after acquiring an additional 16,137 shares during the quarter. Maverick Capital Ltd.'s holdings in Teva Pharmaceutical Industries were worth $466,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $43,000. Compagnie Lombard Odier SCmA purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $54,000. Banque Cantonale Vaudoise purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $74,000. Finally, Brooklyn Investment Group lifted its holdings in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after buying an additional 4,014 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on TEVA. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. Finally, UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Trading Up 2.5%

TEVA stock traded up $0.46 during mid-day trading on Friday, reaching $18.94. 7,802,703 shares of the stock traded hands, compared to its average volume of 9,725,214. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The stock has a market capitalization of $21.72 billion, a PE ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72. The business has a 50-day moving average price of $17.04 and a two-hundred day moving average price of $16.40.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.